New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
Rhea-AI Summary
Longeveron (NASDAQ: LGVN)/b) announced that additional Phase 2a clinical data analysis of its stem cell therapy in mild Alzheimer’s disease was accepted for a poster presentation at the 2026 Alzheimer’s Association International Conference (AAIC) in London, July 12-15, 2026.
The poster, titled “Laromestrocel in Mild Alzheimer’s Disease: Additional Phase 2a Clinical Data Analysis,” will be presented Monday, July 13, 2026, 7:30am–4:15pm BST. According to Longeveron, prior CLEAR MIND Phase 2a results supporting laromestrocel’s therapeutic potential were published in Nature Medicine in March 2025.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – LGVN
On the day this news was published, LGVN declined 2.37%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
LGVN showed a pre-news gain of 9.09%, while tracked biotech peers were mixed, with one in the momentum scan up and one down, indicating stock-specific factors rather than a broad sector move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | HLHS DMC review | Positive | -0.9% | DMC found no new safety issues and recommended completing Phase 2b ELPIS II. |
| May 08 | FDA Type C meeting | Negative | -0.9% | FDA rejected RVEF as primary endpoint and no longer views ELPIS II as pivotal. |
| Feb 25 | Frailty Phase 2b data | Positive | -5.6% | Phase 2b frailty trial showed improved physical condition versus placebo in 148 patients. |
| Jun 24 | HLHS enrollment complete | Positive | +7.8% | Completed enrollment of 40 pediatric HLHS patients in Phase 2b ELPIS II trial. |
| Mar 11 | Alzheimer’s Phase 2a | Positive | +5.4% | Nature Medicine publication showed cognitive and brain-structure benefits in mild Alzheimer’s. |
Clinical trial updates have produced mixed share reactions, with both rallies and selloffs despite generally positive data disclosures.
Historical Comparison
In the past year, LGVN released 5 clinical-trial updates with an average move of 1.18%. This Alzheimer’s Phase 2a analysis and AAIC poster fit into that steady, modest response profile.
Clinical news shows laromestrocel progressing across indications, from Phase 2a Alzheimer’s publication to Phase 2b HLHS enrollment and frailty data, building a multi-program dataset over time.
Regulatory & Risk Context
Reported short positioning is elevated, suggesting potential for sharper volatility and the risk of squeezes or unwind moves if sentiment shifts.
Market Pulse Summary
This announcement reinforces earlier Phase 2a Alzheimer’s results by adding analyses showcased at AAIC. Prior clinical updates triggered varied stock responses, and elevated short interest remains a risk as investors assess future trial and financing needs.
Key Terms
phase 2a medical
stem cell therapy medical
poster presentation technical
peer-reviewed technical
AI-generated analysis. Not financial advice.
MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimer’s disease has been accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference® (AAIC®), to be held July 12-15, 2026 in London, United Kingdom and online.
| Poster Presentation (Exhibit Hall) | |
| Date: | Monday, July 13, 2026 |
| Time: | 7:30am – 4:15pm BST |
| Session: | In-Person Posters Tuesday; Drug Development: Human |
| Topic: | Laromestrocel in Mild Alzheimer’s Disease: Additional Phase 2a Clinical Data Analysis |
Results from the CLEAR MIND Phase 2a clinical trial, which support the therapeutic potential of laromestrocel in the treatment of mild Alzheimer’s disease and provided evidence-based support for further clinical development, were published in the peer-reviewed journal Nature Medicine in March 2025.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; our ability to successfully transition toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for our stem cell therapy laromestrocel in our development programs; the ability to reach alignment with the FDA on a potential path toward regulatory approval; receipt of trial results and other available evidence sufficient to support the Company filing a BLA following the readout of top-line results of the ELPIS II data; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
